People: Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

3.42USD
26 Dec 2014
Price Change (% chg)

$-0.15 (-4.20%)
Prev Close
$3.57
Open
$3.57
Day's High
$3.60
Day's Low
$3.40
Volume
4,423,360
Avg. Vol
3,683,238
52-wk High
$7.97
52-wk Low
$3.26

Search Stocks

Summary

Name Age Since Current Position

Jack Lief

68 2007 Chairman of the Board, President, Chief Executive Officer

Robert Hoffman

48 2012 Chief Financial Officer, Senior Vice President - Finance

Dominic Behan

50 2012 Executive Vice President, Chief Scientific Officer, Director

Steven Spector

49 2012 Executive Vice President, General Counsel, Secretary

Craig Audet

50 2012 Senior Vice President - Operations and Head of Global Regulatory Affairs

William Shanahan

65 2010 Senior Vice President, Chief Medical Officer

Christine White

62 2008 Lead Independent Director

Donald Belcher

75 2003 Independent Director

Scott Bice

71 2003 Independent Director

Harry Hixson

75 2004 Independent Director

Tina Nova

60 2004 Independent Director

Philip Schneider

58 2007 Independent Director

Randall Woods

62 2007 Independent Director

Biographies

Name Description

Jack Lief

Mr. Jack Lief is Chairman of the Board, President, Chief Executive Officer of Arena Pharmaceuticals, Inc. Mr. Lief is a co-founder of Arena and has served as a director and President and Chief Executive Officer since April 1997. Mr. Lief has served as the Chairman of the Board of Directors since October 2007. Mr. Lief served as an advisor and consultant to biopharmaceutical organizations from 1995 to April 1997; as Senior Vice President, Corporate Development and Secretary of Cephalon, Inc., a biopharmaceutical company, from 1989 to 1994; as Director of Business Development and Strategic Planning for Alpha Therapeutic Corporation, a manufacturer of biological products, from 1983 to 1989; and in positions at Abbott Laboratories, a pharmaceutical company, from 1972 to 1983, as the head of International Marketing Research. Mr. Lief serves as the Chairman of the board of directors of ADVENTRX Pharmaceuticals, Inc., a company focused on pharmaceuticals for cancer and infectious disease. Mr. Lief is an Executive Board Member of BIOCOM, a life science association representing 550 member companies in Southern California, and was the Chair of the board of directors of BIOCOM from March 2005 to March 2006. Mr. Lief holds a B.A. from Rutgers University and an M.S. in Psychology (Experimental and Neurobiology) from Lehigh University.

Robert Hoffman

Mr. Robert E. Hoffman has served as Senior Vice President - Finance and Chief Financial Officer of Arena Pharmaceuticals Inc., since June 2012. Mr. Hoffman served as our Vice President, Finance and Chief Financial Officer from August 2011 to June 2012 and previously from December 2005 to March 2011; our Vice President, Finance and Chief Accounting Officer from June 2004 to December 2005; our Vice President, Finance from April 2000 to June 2004; and as our Controller from August 1997 to April 2000. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr. Hoffman serves as a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman is also a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.

Dominic Behan

Dr. Dominic P. Behan is an Executive Vice President, Chief Scientific Officer, Director of Arena Pharmaceuticals, Inc. He is a co-founder of Arena and has served as a director since April 2000 and as Executive Vice President and Chief Scientific Officer since February 2012. Dr. Behan served as Senior Vice President and Chief Scientific Officer from June 2004 to February 2012, and as Vice President, Research from April 1997 to June 2004. Dr. Behan directed research programs at Neurocrine Biosciences, Inc., a biopharmaceutical company, from 1993 to 1997, and was engaged in research at the Salk Institute from 1990 to 1993. Dr. Behan holds a B.Sc. in Biochemistry from Leeds University, England, and a Ph.D. in Biochemistry from Reading University, England.

Steven Spector

Mr. Steven W. Spector is Executive Vice President, General Counsel, Secretary of Arena Pharmaceuticals, Inc. He has served as Executive Vice President and General Counsel since February 2012. Mr. Spector served as Senior Vice President and General Counsel from June 2004 to February 2012, and as Vice President and General Counsel from October 2001 to June 2004. Mr. Spector has served as Secretary since November 2001. Mr. Spector is a member of the board of directors and a former President of the Association of Corporate Counsel, San Diego. Prior to joining Arena, Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. Mr. Spector was outside corporate counsel from 1998 to October 2001. Mr. Spector holds a B.A. and a J.D. from the University of Pennsylvania.

Craig Audet

Mr. Craig M. Audet is Senior Vice President - Operations and Head of Global Regulatory Affairs of Arena Pharmaceutical Inc,. Mr. Audet served as our Vice President, Global Regulatory Affairs from June 2011 to June 2012 and as our Vice President, Regulatory Affairs from April to June 2011. Mr. Audet has over 25 years of experience leading global pharmaceutical and medical device registration and marketing support activities, and extensive experience with clinical trials, registrations, labeling development, product defense, business development and promotion and advertising activities. From December 2003 to August 2010, Mr. Audet served in various positions, and most recently as Vice President, US Regulatory Affairs, for Sanofi-Aventis, US, a pharmaceutical company, where he built and lead a department of 40 regulatory professionals. Mr. Audet served in various positions, and most recently as Senior Director, Global Therapeutic Area Leader, for Pfizer Pharmaceuticals Group, Pfizer, Inc., a pharmaceutical company, from March 1998 to December 2003. Mr. Audet also served as Adjunct Associate Professor in the Graduate Program in Quality Assurance/Regulatory Affairs at Temple University School of Pharmacy from 2002 to 2011. Mr. Audet holds a BS in Biology/Pre-Medicine from Boston College.

William Shanahan

Dr. William R. Shanahan is Senior Vice President, Chief Medical Officer of Arena Pharmaceuticals, Inc., since June 2010. Dr. Shanahan served as Vice President and Chief Medical Officer from March 2004 to June 2010. Dr. Shanahan served as Chief Medical Officer for Tanox, Inc., a biopharmaceutical company, from 2000 to March 2004; in positions at Isis Pharmaceuticals, Inc., a biopharmaceutical company, from 1994 to 2000, most recently as Vice President, Drug Development; as Director, Clinical Research for Pfizer Central Research, a pharmaceutical company, from 1989 to 1994; and in various positions at Searle Research & Development, a pharmaceutical company subsequently acquired by Pfizer, from 1986 to 1989, most recently as Director, Clinical Research. Dr. Shanahan holds an A.B. from Dartmouth College, an M.D. from the University of California, San Francisco and a J.D. from Loyola University, Chicago.

Christine White

Dr. Christine Anna White is Lead Independent Director of Arena Pharmaceuticals, Inc. Dr. White served in senior positions with Biogen Idec Inc., a biopharmaceutical company, from 1996 to 2005, as Senior Vice President, Global Medical Affairs; as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego from 1994 to 1996; and on the clinical staff and in various positions in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, from 1984 to 1994, most recently as Chairman, Department of Medicine. Dr. White serves as a member of the board of directors of Marshall Edwards, Inc., an oncology company focused on the clinical development of novel anti-cancer therapeutics. Within the past five years, Dr. White served as a member of the board of directors of Genoptix, Inc., a medical laboratory diagnostics company, Pharmacyclics, Inc, a pharmaceutical company developing products to treat cancer and other diseases, and Monogram Biosciences, Inc., a life sciences company. Dr. White holds a B.A. in Biology and an M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.

Donald Belcher

Mr. Donald D. Belcher is an Independent Director of Arena Pharmaceuticals, Inc., since December 16, 2003. Mr. Belcher served as Chairman of the board of directors of Banta Corporation, a printing and supply-chain management company, from 1995 to 2004, Chief Executive Officer from 1995 to 2002 and President from 1994 to 2001. Mr. Belcher holds a B.A. from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business.

Scott Bice

Mr. Scott H. Bice is an Independent Director of Arena Pharmaceuticals, Inc., since December 16, 2003. Mr. Bice has been the Robert C. Packard Professor at the University of Southern California Law School since 2000, where he served as Dean from 1980 to 2000. Mr. Bice has experience on several corporate boards, including Imagine Films, from 1992 to 1994; Western and Residence Mutual Insurance Companies, from 1996 to 2003; and Jenny Craig, from 1996 to 2002. Mr. Bice holds a B.S. in finance and a J.D. from the University of Southern California.

Harry Hixson

Dr. Harry F. Hixson Jr., Ph.D is an Independent Director of Arena Pharmaceuticals, Inc., since September 15, 2004. Dr. Hixson has served as the Chief Executive Officer of Sequenom, Inc., a genomics company, since September 2009, and as Chairman of its board of directors since 2003. Dr. Hixson served as Chief Executive Officer of BrainCells Inc., a neurogenesis-based drug discovery and development company, from 2004 to 2005; as Chief Executive Officer of Elitra Pharmaceuticals Inc., a biopharmaceutical company, from 1998 to 2003; and in various management positions with Amgen Inc., a biopharmaceutical company, from 1985 to 1991, most recently as President and Chief Operating Officer. Within the past five years, Dr. Hixson served as a member of the board of directors of NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company, and Discovery Partners International Inc., a drug discovery services company that was acquired by Infinity Pharmaceuticals, Inc. Dr. Hixson holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from the University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University.

Tina Nova

Dr. Tina S. Nova, Ph. D., is an Independent Director of Arena Pharmaceuticals, Inc., since September 15, 2004. Dr. Nova is a co-founder of Genoptix, Inc., a medical laboratory diagnostics company, and has served as its President since 2000. Dr. Nova also served as Genoptix’ Chief Executive Officer and as a member of its board of directors from 2000 until Novartis AG acquired Genoptix in February 2011. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, and she served as its Chief Operating Officer and President from 1994 to 2000. Dr. Nova served as Chief Operating Officer of Selective Genetics, a targeted therapy, biotechnology company, from 1992 to 1994, and in various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, from 1988 to 1992, most recently as Executive Director of New Leads Discovery. Dr. Nova was the Chair of the board of directors of BIOCOM from March 2001 to March 2002. Dr. Nova holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.

Philip Schneider

Mr. Phillip M. Schneider is an Independent Director of Arena Pharmaceuticals, Inc., since December 11, 2007. Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2002, most recently as Senior Vice President and Chief Financial Officer. Prior to his association with IDEC, Mr. Schneider held management positions at Syntex Pharmaceuticals Corporation and was previously with KPMG LLP. Mr. Schneider is a member of the board of directors of Gen-Probe Incorporated, a medical diagnostics company. Within the past five years, Mr. Schneider served as a member of the board of directors of Micromet, Inc., a biopharmaceutical company, and CancerVax Corporation, a biotechnology company that merged with Micromet AG to become Micromet, Inc. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.

Randall Woods

Mr. Randall E. Woods is an Independent Director of Arena Pharmaceuticals, Inc., since December 11, 2007. Mr. Woods has served as the Managing Director of Eden Woods Investments, an investment company, since May 2011. Mr. Woods served as the President and Chief Executive Officer and a member of the board of directors of Sequel Pharmaceuticals, Inc., a pharmaceutical company, from September 2007 to June 2011; as the President and Chief Executive Officer of NovaCardia, Inc., a pharmaceutical company that was acquired by Merck & Co., Inc., from April 2004 to September 2007; as the President and Chief Executive Officer of Corvas International, Inc., a biopharmaceutical company, from 1996 to 2003; in various senior positions at Boehringer Mannheim’s US pharmaceutical operations, from 1993 to 1996, as President; and before then served more than 20 years at Eli Lilly & Company in sales and marketing positions. Mr. Woods is the chairman emeritus of the advisory board of the University of California, San Diego’s Sulpizio Cardiovascular Center. Mr. Woods is an Executive Board Member of BIOCOM, and was the Chair of the board of directors of BIOCOM for 2009. Mr. Woods holds a B.S. in Biology and Chemistry from Ball State University and an M.B.A. from Western Michigan University.

Basic Compensation

Name Fiscal Year Total

Jack Lief

3,967,140

Robert Hoffman

1,470,320

Dominic Behan

2,326,830

Steven Spector

2,241,700

Craig Audet

--

William Shanahan

1,491,500

Christine White

--

Donald Belcher

--

Scott Bice

--

Harry Hixson

--

Tina Nova

--

Philip Schneider

--

Randall Woods

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Jack Lief

626,850 2,175,216

Robert Hoffman

151,250 1,103,915

Dominic Behan

547,500 3,457,747

Steven Spector

266,665 1,868,591

Craig Audet

0 0

William Shanahan

105,000 836,850

Christine White

0 0

Donald Belcher

0 0

Scott Bice

0 0

Harry Hixson

0 0

Tina Nova

0 0

Philip Schneider

0 0

Randall Woods

0 0
Search Stocks